Scientific publications for BioPredictive non-invasive diagnostics
Peer-reviewed studies validating BioPredictive blood-test diagnostics for liver disease — from first-in-class development cohorts to long-term meta-analyses.
32/433 Publications
-
Toward non-invasive assessment strategies in autoimmune hepatitis.
-
Pharmacotherapeutic efficacy on noninvasive fibrosis progression in nonalcoholic fatty liver disease: a systematic review and network meta-analysis. Review
-
Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study.
-
Biomarkers for liver disease in urea cycle disorders.
-
The Association of Histologic and Noninvasive Tests With Adverse Clinical and Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis.
-
Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus.
-
Editorial: FibroTest to predict liver-related mortality in NAFLD. Should this change the diagnostic algorithm in NAFLD?
-
Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers.
-
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.
-
Letter: APRI and FIB-4 do not correlate with Fibrosure in the evaluation of liver fibrosis in hepatitis C patients.
-
Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action. Review
-
Noninvasive Testing for Nonalcoholic Steatohepatitis and Hepatic Fibrosis in Patients With Psoriasis Receiving Long-term Methotrexate Sodium Therapy.
-
Predictive value of biomarkers of hepatic fibrosis in adult Fontan patients.
-
Role of Non-hepatic Medical Comorbidity and Functional Limitations in Predicting Mortality in Patients with HCV.
-
Current complications and challenges in nonalcoholic steatohepatitis screening and diagnosis.
-
Management of the patient with SVR. Review
-
Coffee and Caffeine Are Associated With Decreased Risk of Advanced Hepatic Fibrosis Among Patients With Hepatitis C.
-
Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Key publication
-
Liver fibrosis in adults with Fontan palliation: Do common screening studies predict disease severity?
-
Successful treatment with telaprevir-based regimens for chronic hepatitis C results in significant improvements to serum markers of liver fibrosis.
-
Efficacy and safety of tenofovir disoproxil fumarate in Asian-Americans with chronic hepatitis B in community settings.
-
FibroSURE as a noninvasive marker of liver fibrosis and inflammation in chronic hepatitis B.
-
Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review.
-
The new paradigm of hepatitis C therapy: integration of oral therapies into best practices.
-
Higher serum testosterone is associated with increased risk of advanced hepatitis C-related liver disease in males.
-
Racial differences in the association between adiposity measures and the risk of hepatitis C-related liver disease.
-
Cost effectiveness of fibrosis assessment prior to treatment for chronic hepatitis C patients.
-
FibroSURE and FibroScan in relation to treatment response in chronic hepatitis C virus.
-
Non-invasive markers for hepatic fibrosis.
-
An evaluation of the potential cost-effectiveness of non-invasive testing strategies in the diagnosis of significant liver fibrosis.
-
An independent and prospective comparison of two commercial fibrosis marker panels (HCV FibroSURE and FIBROSpect II) during albinterferon alfa-2b combination therapy for chronic hepatitis C.
-
Progression of liver fibrosis among injection drug users with chronic hepatitis C.
Showing the full result list. The page is server-rendered and not paginated.